<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AT III substitution is indicated in patients with inherited <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> if these patients suffer <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp>, if they have to be treated surgically and in the case of pregnancy in women with AT III deficiency who have an abortion or <z:mp ids='MP_0005048'>thrombosis</z:mp>, as well as during and after delivery </plain></SENT>
<SENT sid="1" pm="."><plain>In acquired <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> such as in patients with liver <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> or the <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo>, AT III substitution may be necessary if thrombotic complications occur </plain></SENT>
<SENT sid="2" pm="."><plain>AT III substitution has been propagated especially in patients with polytrauma, <z:e sem="disease" ids="C0036690" disease_type="Disease or Syndrome" abbrv="">septicaemia</z:e>, <z:chebi fb="0" ids="53092">DIC</z:chebi>, <z:hpo ids='HP_0006554'>acute liver failure</z:hpo> and in <z:e sem="disease" ids="C0040524,C0032914" disease_type="Disease or Syndrome" abbrv="">toxaemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In AT III substitution initial doses of 1 U/kg body weight are used to reach a 1,5% rise in plasma AT III level </plain></SENT>
<SENT sid="4" pm="."><plain>If AT III turnover is <z:mpath ids='MPATH_458'>normal</z:mpath> a rise above 80% of <z:mpath ids='MPATH_458'>normal</z:mpath> should be achieved </plain></SENT>
<SENT sid="5" pm="."><plain>If AT III turnover is increased, much higher initial and maintenance doses may be needed to normalize plasma AT III levels and to block <z:chebi fb="0" ids="53092">DIC</z:chebi> </plain></SENT>
</text></document>